Positions

Overview

  • I am currently assistant professor and associate scientist at the University of Alabama at Birmingham Comprehensive Cancer Center (UABCCC). I am board certified in Internal Medicine, Hematology and Oncology. My focus of interest is LYMPHOMA (Hodgkin lymphoma, Non Hodgkin lymphoma-T cell and B cell lymphomas). I specialize in treatments all types of lymphoma in my clinic. I am also involved in lymphoma related research, which includes genomic and proteomic (gene and protein related) studies in various kinds of lymphomas. As a clinical investigator I am also part of many clinical trials as principal investigator or sub investigator particularly in lymphomas. Many new promising targeted and immunologic treatments for lymphomas are being developed at UABCCC, which patients of lymphoma can benefit.

    My passion is to develop targeted and immunologic therapies in lymphomas with less toxicities and more effectiveness.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 A review of chimeric antigen receptor T-cells in lymphoma 2019
    2019 Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study 2019
    2019 The impact of structural factors on diagnostic delay in diffuse large B-cell lymphoma 2019
    2019 AIDS-related Kaposi sarcoma, version 2.2019 2019
    2019 B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines 2019
    2019 Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era 2019
    2018 Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting as Transverse Myelitis 2018
    2018 Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models 2018
    2018 Congestive heart failure in older adults diagnosed with follicular lymphoma: A population-based study 2018
    2018 Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets 2018
    2018 Cancer in people living with HIV, version 1.2018: Clinical practice guidelines in oncology 2018
    2018 Imitating the great imitator: The intersection of sarcoidosis and hodgkin’s lymphoma a report of two cases 2018
    2018 Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary education 2018
    2018 T-Cell Lymphomas, Version 2.2018 Featured Updates to the NCCN Guidelines 2018
    2017 C-MYC–positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy 2017
    2017 PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: High response rate but frequent GVHD 2017
    2017 Treatment approaches of hard-to-treat non-Hodgkin lymphomas 2017
    2017 Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies 2017
    2017 Diagnostic, prognostic and therapeutic role of CD30 in lymphoma 2017
    2017 Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets 2017
    2017 Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma 2017
    2016 Amitkumar Mehta on the Immunomodulating Effects of Targeted Therapy for Multiple Myeloma 2016
    2016 Amitkumar Mehta on the immunomodulating effects of targeted therapy for multiple myeloma 2016
    2016 Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy 2016
    2016 Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin 2016
    2015 Development and Integration of Antibody–Drug Conjugate in Non-Hodgkin Lymphoma 2015
    2015 High throughput kinomic profiling of human clear cell renal cell carcinoma identifies kinase activity dependent molecular subtypes 2015
    2015 Advanced prostate cancer presenting as bilateral testicular hydrocele 2015
    2015 Tivozanib: Status of Development 2015
    2015 Current trends in the treatment of mantle cell lymphoma 2015
    2015 Novel agents for the treatment of Hodgkin lymphoma 2015
    2014 A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma 2014
    2014 Disseminated fusariosis during acute myelogenous leukemia induction treatment 2014
    2014 How do i recommend extended adjuvant hormonal therapy? 2014
    2014 Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy 2014
    2014 Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma 2014
    2014 Tivozanib for the treatment of renal cell carcinoma: Results and implications of the TIVO-1 trial 2014
    2014 Update in systemic therapy of urologic malignancies 2014
    2013 Heparin induced thrombocytopenia: Review 2013
    2013 A cautionary tale for probiotic use in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT 2013
    2013 Current advances in understanding and managing secondary brain metastasis 2013
    2011 Massive pulmonary embolism and cardio-pulmonary resuscitation leading to disseminated intravascular coagulation 2011
    2011 An unusual case of squamous cell carcinoma of lung with metastases to the heart 2011

    Chapter

    Year Title Altmetric
    2015 Mantle cell lymphoma: Current treatment strategies in the era of targeted agents.  35-62. 2015

    Research Overview

  • Clinical:
    My research area involves:

    -Development of newer agents and combination of newer biologic agents in various kinds of lymphomas. I am principal investigator and sub investigator in many Phase I, II or III clinical trials. My passion is to develop biologic therapies with less toxicities and more effectiveness.

    -Survivorship research which involves well being of all lymphoma patients who have been exposed to chemotherapy, radiation therapy or had bone marrow transplant in past.

    -Development of blood test to diagnose and monitor lymphoma during and after treatment. This highly sensitive blood test identifies tumor related genes to monitor lymphoma. This test is still in developmental phase but may eliminate need for biopsies in future.

    Translational:
    -Lymphomas are biologically diverse tumors. Learning about their genetic make up and protein expression help us understand about their biology and develop new targeted and biological treatments. I collaborate with basic scientists and analyze lymphoma biopsies to understand biologic diversity and develop newer therapies.

    UAB Lymphoma program:
    UABCCC lymphoma program is comprehensive program involving specialists (medical oncology, surgical oncology, radiation oncology, Bone marrow transplant, survivorship and integrative medicine) and great nurses.

    Apart from lymphomas, I also see patients with blood cancers (malignant hematology) and blood related disorders (benign hematology).

    You can call my clinic (205-934-5077) or office (205-996-8400) for initial consultation, second opinions or clinical trials.

    Special Interests:

    Lymphoma
    Diffuse large B-cell
    Follicular lymphoma
    Hodgkin Lymphoma
    Mantle Cell Lymphoma
    T-Cell Lymphoma
    Other B-Cell Lymphomas
    Agressive Lymphomas
    Any kind of skin lymphomas (Cutaneous T cell/B cell lymphomas)
    Targeted Therapy
    Clinical Trials
    Disparity Research
  • Principal Investigator On

  • Private Grant  awarded by TG THERAPEUTICS 2019 - 2024
  • Private Grant  awarded by KITE PHARMA 2019 - 2024
  • Private Grant  awarded by MIRAGEN THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2019 - 2024
  • Private Grant  awarded by Genentech 2019 - 2024
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2018 - 2023
  • Private Grant  awarded by Genentech 2018 - 2023
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2018 - 2023
  • Private Grant  awarded by PHARMACYCLICS, INC. 2018 - 2023
  • Private Grant  awarded by IMMUNOGEN, INC. 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2022
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2022
  • Private Grant  awarded by ADC THERAPEUTICS SA 2019 - 2022
  • Private Grant  awarded by Genentech 2019 - 2022
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2019 - 2022
  • Private Grant  awarded by FORTY SEVEN, INC. 2018 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by EPIZYME - NEW 2016 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2018 - 2020
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2015 - 2020
  • Private Grant  awarded by Gilead Sciences 2018 - 2020
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2020
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2018 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2020
  • Private Grant  awarded by Genentech 2018 - 2020
  • Outcomes of Limited Stage Diffuse Large B-Cell Lymphoma with MYC Rearrangement  awarded by Roswell Park Cancer Institute 2018 - 2020
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2015 - 2020
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2020
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2017 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2018
  • Private Grant  awarded by PHARMACYCLICS, INC. 2015 - 2018
  • Private Grant  awarded by Genentech 2016 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016
  • Private Grant  awarded by MedImmune 2014 - 2016
  • Investigator On

  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2019 - 2025
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2023
  • Private Grant  awarded by IOVANCE BIOTHERAPEUTICS INC. 2018 - 2023
  • Private Grant  awarded by ROCHE TCRC, INC. 2018 - 2023
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2023
  • Private Grant  awarded by MERCK & COMPANY, INC. 2019 - 2023
  • Private Grant  awarded by AFFIMED GMBH 2016 - 2021
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2021
  • Private Grant  awarded by MedImmune 2010 - 2020
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC. 2015 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2015 - 2020
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2018 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by AILERON THERAPEUTICS 2015 - 2020
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2018 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by Genentech 2015 - 2018
  • Private Grant  awarded by TESARO, INC. 2016 - 2018
  • Private Grant  awarded by Gilead Sciences 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2013 - 2018
  • Private Grant  awarded by FORTY SEVEN, INC. 2017 - 2018
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014 - 2018
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2018
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2017
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2017
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2015 - 2017
  • Private Grant  awarded by GlaxoSmithKline 2013 - 2016
  • Private Grant  awarded by MedImmune 2012 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015 - 2016
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Whole Exome and Comprehensive Kinomics Analysis of Penile Squamous Cell Carcinoma  awarded by Conquer Cancer Foundation of ASCO 2014 - 2015
  • Private Grant  awarded by AILERON THERAPEUTICS 2015
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2014
  • Education And Training

  • George Washington University Hospital, Residency 2011
  • UAB Hospital, Postdoctoral Fellowship 2014
  • Full Name

  • Amitkumar Mehta